Moderna Shares Jump on FDA's COVID-19 Vaccine Approval Framework

Strategic Insights -

Moderna Inc's (NASDAQ:MRNA, ETR:0QF) shares surged by more than 6.5% on Tuesday, driven by the US Food and Drug Administration's (FDA) updated guidelines for COVID-19 vaccine approvals. The new framework maintains the status quo for the company's core market, particularly for individuals aged 65 and older or those aged six months to 64 years at high risk. Analysts estimate that these groups account for a majority of COVID-19 vaccinations, with at least 40% to 50% of annual vaccinations among those 65 and older.

Key Takeaways:

  • The FDA's updated guidance does not change how COVID-19 vaccines are authorized for individuals aged 65 and older or those aged six months to 64 years who are at high risk.
  • Analysts estimate that these groups account for a majority of COVID-19 vaccinations, with at least 40% to 50% of annual vaccinations among those 65 and older.
  • Jefferies analysts noted that the framework aligns with recent recommendations from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), which had leaned toward risk-based vaccination strategies instead of universal guidelines.
  • The updated framework introduces new requirements for placebo-controlled trials in healthy individuals aged six months to 64 years, but it remains unclear whether these studies will be needed annually or only for next-generation or combination vaccines.
  • Jefferies analysts wrote that running placebo-controlled trials each year could prove difficult given the tight timeline between strain selection in May or June and vaccine rollout in late summer.
  • Vaccines will continue to be approved based on immunogenicity data - how well a vaccine triggers an immune response - rather than infection rates, allowing for a faster pathway to market ahead of the fall and winter respiratory virus season.

Statistics:

  • Moderna Inc's shares jumped by more than 6.5% on Tuesday.
  • Analysts estimate that at least 40% to 50% of annual COVID-19 vaccinations are among those 65 and older.
  • The FDA's updated guidance does not change the requirement for placebo-controlled trials for individuals aged six months to 64 years who are not at high risk.

Sources:

  • Moderna Inc (NASDAQ:MRNA, ETR:0QF) - company website
  • " FDA Unveils New Framework for COVID-19 Vaccine Approvals" - original news article
  • Jefferies - investment bank and financial services company
  • US Food and Drug Administration (FDA) - regulatory agency
  • Centers for Disease Control and Prevention (CDC) - public health agency